TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Shift of accommodation in scotopic luminance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Permanent Spinal Cord Stimulator Implantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of clinician administered rescue boluses
Endpoint domain: Adverse events/effects
Primary endpoint: Ratio of the number of PCEA boluses requested to the number of PCEA boluses delivered
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of patients achieving NCI CTCAE v5.0 - Palmar-Plantar Erythrodysesthesia (PPE) grade 0 or 1
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients achieving IGA-HFSR grade 0 or 1
Endpoint domain: Adverse events/effects
Primary endpoint: Immediate tolerability and safety
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of diagnostic specimens
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain, function and alignment of the treated toe
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Treatment-Emergent Adverse Events (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Stroke/Death Occurrence
Endpoint domain: Mortality/survival
Primary endpoint: Aneurysm Occlusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tidal volume size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: KOOS knee score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Participants Experiencing Graft Failure
Endpoint domain: Mortality/survival
Primary endpoint: Degree of contrast enhancement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimum Inhibitory Concentration (MIC) of KAE609
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: change in Modified Barthel Index (mBI)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percent Change of Global Face Total Acne Lesion Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of success at the 24-month follow-up visit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease-free Survival Status
Endpoint domain: Mortality/survival
Primary endpoint: Persistent Postsurgical Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of non emergency room clinician visits
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Rate of successful mastectomy strategy with immediate reconstruction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mean absolute change in haemoglobin (Hb)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants With Any Adverse Event (AE) During the Treatment Phase
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Any Adverse Event (AE) During the Follow-up Phase
Endpoint domain: Adverse events/effects
Primary endpoint: Safety and tolerability of CRx-197
Endpoint domain: Adverse events/effects
Primary endpoint: Change in pain score (Faces Pain Scale-Revised)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pain score (numeric pain rating scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Seroprotected Participants at Month 7
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Seroprotected Participants at Month 9
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Total Number of Participants With One or More Injection-Site Adverse Experiences
Endpoint domain: Adverse events/effects
Primary endpoint: Total Number of Participants With a Maximum Temperature >= 100.0F / 37.8C
Endpoint domain: Adverse events/effects
Primary endpoint: Total Number of Participants With Serious Vaccine-Related Clinical Adverse Experiences
Endpoint domain: Adverse events/effects
Primary endpoint: Operative and peri-operative outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Increment of CD4+ cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rheumatoid arthritis patient´s disease activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rheumatoid arthritis patient´s quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Rheumatoid arthritis patient's disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Preliminary pooled keratinocyte carcinoma event rate
Endpoint domain: Mortality/survival
Primary endpoint: Taxa abundance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients requiring intervention for UGIB
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: occurrence of plantar foot ulceration wound
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Sensitivity of the new MRI method
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lesion detection rate of the new MRI method
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in Liebowitz Social Anxiety Scale (LSAS) total score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Quality of Recovery 15 Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence of Severe (Grade 3 or 4) TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Drug-Related TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Best Glottic View Obtained
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: CD8+ cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Neuropsychological evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success of first breastfeeding
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Newborn temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of treatment-emergent adverse events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Ischemic stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Concentration of Ertapenem in Colorectal Tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in reading single words
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Improvement in naming
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Ratio of Cerebral N Acetyl-Aspartate (NAA) / Cerebral Creatine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Area Under the Curve (AUC) of Numeric Rating Scale at Rest (NRS-R) Pain Intensity Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall safety profile including adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: CASPER instrument sum score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Levels of Glutamate in the basal ganglia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in substance use (relapse)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in moderate to vigorous physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Triglycerides serum levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Visual Analog Scale (VAS) Pain Score (Per Protocol)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Analog Scale (VAS) Pain Score (As Treated)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival with good neurologic outcome
Endpoint domain: Mortality/survival
Primary endpoint: Intra spinal pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spinal metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Collagen expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in the number of CBCT rescans
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Conners' Adult ADHD Rating Scales-Self-Report
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Adult ADHD Quality of Life-29
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Response Rate (CR + PR rate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Carotid intima media measurement change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Caregiver's level of burden
Endpoint domain: Resource use
Endpoint subdomain: Societal/carer burden
Primary endpoint: Change in Dysphagia Outcome and Severity Scale (DOSS) Rating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dysphagia Handicap Index (DHI)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Green Paranoid Thoughts Scale (GPTS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Gene sequencing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in Circumference of Upper Thigh
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in Circumference of Mid Thigh
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neuropsychiatric Inventory (NPI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Dementia Rating Scale (CDR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geriatric Depression Scale (GDS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Scores at Week 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sleep Quality/Quantity Scores (PSQI)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Number of Participants With Hypersensitivity Adverse Reaction
Endpoint domain: Adverse events/effects
Primary endpoint: Intraepidermal Nerve Fiber Density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Sudomotor Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Ocular Nerve Fiber Density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: 1- and 3-years recurrence rate after surgery
Endpoint domain: Mortality/survival
Primary endpoint: Blood Vitamin D level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Meibomian Glands Yielding Liquid Secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Intensity in the target knee after movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration time of mechanical ventilation (weaning)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Bronchoalveolar Eosinophils
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: AUC from zero to the last sampling point (AUCt) of sertraline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum plasma concentration (Cmax) of sertraline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in average stool frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change from baseline of number of mast cell per mm2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: HBsAg seroconversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Patient with more than 2 points on the ODORATEST
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Size of myocardial perfusion abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Overall Liking of Apple Crisp
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Overall Liking of Tea
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Overall Liking of Oatmeal
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants with Adverse Events and Adverse Drug Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Headache Impact Test-6 (HIT-6) Score Using a 5-Point Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Perfusion of Wound Closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Motor changes of the upper esophageal sphincter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Changes in motor function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global assessment of efficacy by investigator
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Emergency Department to Inpatient Conversion Rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: videofluoroscopy data completeness
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: length of radiation exposure time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma pharmacokinetics of dexmedetomidine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Graded Redefined Assessment of Strength, Sensibility and Prehension (GRASSP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immediate change in the composite score of executive functions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Immediate change in the composite score of episodic memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Immediate change in brain activations during executive functions: multi-tasking
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Immediate change in brain activations during executive functions: working memory updating
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Aortic Pulse-wave Velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Clinical performance of Xpert Flu
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Residual significant tricuspid regurgitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Initial parasitological cure at day 29
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Overall Response Rate - Actionable Genetic Alteration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Response Rate - Non-Actionable Genetic Alteration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Patients With a ≥ 50% PSA Decline Post-therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Pressure Pain threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cervical Intraepithelial Neoplasia Grade II or more severe
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Regional cerebral blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of participants with clinically significant changes in electrocardiogram parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in birth self-efficacy level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Peak Epinephrine During Hypoglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Driver club speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 7-iron club speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Driver distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 7-iron distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Who Developed Psoriatic Arthritis (PsA)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Who Developed Signs or Symptoms of PsA
Endpoint domain: Adverse events/effects
Primary endpoint: Subjective Improvement - Day 3
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: COPD acute exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change from Baseline on the Clinician-Administered PTSD Scale for DSM-5
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression-free survival (PFS1)
Endpoint domain: Mortality/survival
Primary endpoint: Total Progression-free survival (PFST)
Endpoint domain: Mortality/survival
Primary endpoint: Number of Subjects Achieving Clinical Cure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with Major Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: PIGF levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: niacin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Hamilton Depression Rating Scale-17 Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Adherence to study protocol activities
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Smoking cessation verified by carbon monoxide test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: OMERACT-OARSI Responder Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective Response (CR or PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Clinical Global Impression Scale - Improvement (CGI-I)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Reduction in Frequency of Infliximab Administration
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Symptom-Medication-Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of patients with treatment success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patients perceived pain during injection
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Relative bioavailability of E1 versus E2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with any treatment-emergent adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma concentration of BOS172767 enantiomers 1 and 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in IFNg/IL2 dual color fluorospot number
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Hydrogen/methane breath testing (hbt)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: IL6 measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Safety and performance of Confirm Rx™
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients developing grades III/IV Bearman regimen-related toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Achieving PASI Score < 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nail Bed Clearing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antibody titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Evolution of sex ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients showing improvement in CRP on LOBS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence and severity of adverse events and adverse drug reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of Placental Malaria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Incidence of Malaria in Pregnant Women
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Incidence of Malaria in Infants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Survival free from hepatic decompensation
Endpoint domain: Mortality/survival
Primary endpoint: Adherence to health regimens
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Methaemoglobin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes